Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed + cisplatin versus tegafur + cisplatin with concurrent IMRT for locally advanced esophageal cancer
ChiCTR1900021082Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of raltitrexed, cisplatin and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Objective response rate, Disease control rate and 2 more. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
raltitrexedcisplatintegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900021082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021082.